Status:
UNKNOWN
Potential Role of Inflammasome NLRP3 And IL-1B Gene Expression in COVID-19 Patients: Impact of Ferretin and D -Dimer.
Lead Sponsor:
Assiut University
Conditions:
Inflammasome NLRP3 And IL-1B Gene Expression in COVID-19 Patients
Eligibility:
All Genders
18-90 years
Brief Summary
2.1 Study the role of NLRP3 inflammasome in COVID-19 patients. 2.2 Study the gene expression of NLRP3 and IL-1β in blood samples of COVID-19 patients and compare to apparently healthy subjects. 2.3 C...
Detailed Description
Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a viral infection that results in respiratory disease, which can evolve into multiorgan fa...
Eligibility Criteria
Inclusion
- Adult Patient aged 18years and over presented to Assiut University Hospital
- Suspected of covid19 because of the presence of symptoms suggestive of pneumonia (fever\>38) and at least one of the following symptoms ;cough, dyspnea, tachpnea or hypoxia
- having RT-PCR (confirmed positive PCR)
- Chest CT within 5 days of initial PCR
Exclusion
- Cases less than 18 years old
- Cancer patients (affect result of study as they have disrubted level of these biomarker)
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT06080750
Start Date
January 1 2023
End Date
January 1 2025
Last Update
October 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Biochemistry department,Faculty of medicine
Asyut, Egypt